Rezvilutamide with hormone therapy for high-risk salivary duct cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a new drug, Rezvilutamide, combined with standard hormone therapy for people with a rare and aggressive type of salivary gland cancer that has a high risk of coming back. The treatment aims to reduce the chance of cancer returning after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of salivary gland cancer called salivary duct carcinoma, and it is stage 3 or 4.
- You have already had surgery to remove the cancer, and you are either planning, currently receiving, or have finished radiation therapy after surgery.
- Your cancer cells tested positive for a protein called androgen receptor (AR).
- Your blood counts, kidney function, and liver function are within certain healthy ranges.
- You have not received previous treatment that targets the androgen receptor pathway for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, rezvilutamide, combined with standard hormone therapy for men with prostate cancer that has spread but still responds to hormone treatment. The goal is to see if this drug helps control the cancer longer than the usual treatment alone.
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
This trial tests a combination of two hormone therapies (darolutamide plus androgen deprivation therapy) given after surgery to remove the prostate, to see if it helps prevent the cancer from coming back in men with high-risk prostate cancer. The goal is to see if this treatment can keep the cancer from spreading or returning.
This Phase 2 trial studies whether adding dutasteride to standard anti-androgen therapy can shrink or slow an advanced salivary gland cancer. It is for cancers that test “androgen receptor (AR) positive,” meaning they may respond to medicines that block male-hormone signals.
This trial tests whether adding a new oral hormone blocker (rezvilutamide) to standard salvage radiation and hormone therapy can better control prostate cancer that has come back (rising PSA) after surgery.
This trial tests a combination of two targeted drugs for advanced salivary gland cancer that has spread or cannot be removed with surgery. The drugs may block hormones and slow cancer growth, potentially helping people whose tumors have specific markers.
Hear when a new Salivary Gland Neoplasm Duct trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.